Share Name Share Symbol Market Type Share ISIN Share Description
Allergy Therapeutics Plc LSE:AGY London Ordinary Share GB00B02LCQ05 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 11.75 11.50 12.00 11.75 11.75 11.75 33,940 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 68.3 -6.9 -1.3 - 76

Allergy Therapeutics Share Discussion Threads

Showing 3826 to 3848 of 3850 messages
Chat Pages: 154  153  152  151  150  149  148  147  146  145  144  143  Older
DateSubjectAuthorDiscuss
26/9/2019
19:52
https://www.hardmanandco.com/wp-content/uploads/2019/09/AGY-FY2019-results-update-26-September-2019.pdf
nquaile875
26/9/2019
19:23
I do believe the strong cash position underpins the company in the coming year and this will be supplemented by a further £3.2m contribution in the next financial year as the legal costs are received. Lot's of 'what if's' to speculate on in terms of next phase trials however the short term benefit is a successful launch of its existing products into new markets which would help the share price immensely.
catch007
26/9/2019
14:17
Video with CEO Manuel on yesterdays results. Also runs through their drug pipeline & lessons learnt from the failed clinical trial: hTTps://youtu.be/C0WAmBSSnVY
macc1
25/9/2019
10:17
Nothing that we did not expectThe China news is much awaited now impo
jimmyloser
25/9/2019
07:41
Well the results are certainly steady. Would be nice if this prompted some further share price recovery but this being AIM I won't be surprised if it doesn't.
audigger
20/9/2019
21:09
Steady as she goes for AGY, which seems below most people's radar. Good for you, catch007, and I totally agree that this is a decent company with credible fundamentals and it looks undervalued. Looking forward to Wednesday, 25th, when AGY reveals FY figures for year-end 30/6/19. I've followed AGY for years, regretting not getting in many moons ago at about 7p. Then I got what Anthony Bolton, the former star stock-picker, calls "a mulligan"- a golfing expression where you get a second shot without penalty- and I got in again after the March collapse. Very good luck everybody !
enteleon
06/9/2019
11:06
Thank you timbo I bought a tranche yesterday at 11.45p to add to my holding and average down my buying price. It looks seriously undervalued to me.
catch007
05/9/2019
10:38
timbo003 - any feedback you can share please?
catch007
04/9/2019
17:37
They will be presenting tonight at the London shares magazine investor meeting, I'll be there
timbo003
04/9/2019
17:22
For a company of this quality to be lying at 11 pence is beyond belief. Okay they have spent millions and failed twice but this is cutting edge technology and base sales continue to grow along with a wide developing portfolio. The arrival of possible Chinese linked investors is hopefully a good sign. I am also hoping that on the 25th they are able to announce a market leading Chinese distributor, that could fire up interest.
jimmyloser
20/8/2019
17:42
Was that Skygem picking up a few more?
ewanwhose
01/8/2019
15:52
Brexit nerves impacting?
jimmyloser
17/7/2019
18:38
... But not quite enough to top up...
ewanwhose
17/7/2019
11:45
Bit of a sharp pull back....
audigger
11/7/2019
07:21
Video from FD Nick Wykeman re: this mornings trading update: hTTps://youtu.be/SvjBtruZ528
macc1
27/6/2019
14:24
Looks almost back to where we started yesterday. Disappointing end to the day
richsawko
27/6/2019
10:50
Didn't see that coming. Certainly reinforces the belief that the management team are on top of things. Proving to be a bit of a roller coaster ride this year! What would be impressive is if they can pull a rabbit out of the hat with a more favourable interpretation of the B301 Phase III trial for the birch product.
audigger
27/6/2019
08:03
Plenty of cash and can we dare hope for a bottom-line profit?
ewanwhose
27/6/2019
07:15
Breaking news Allergy Therapeutics plc ("Allergy Therapeutics", "ATL" or the "Group") Successful litigation settlement relating to PQ Grass Phase II Trial 27 June 2019 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, announces that it has received a $7.6m settlement from Inflamax Research Inc. ("Inflamax") in relation to legal proceedings about the previously disclosed inconclusive Phase II Grass MATA MPL trial which took place in the USA in 2015-16. Inflamax has also agreed to pay a substantial part of the Group's legal costs. The clinical trial (G204) used mobile challenge chambers provided by Inflamax and preceded the successful Grass MATA MPL trial (G205) which the Group reported in June 2018. The Group commenced legal proceedings in the English High Court against Inflamax in March 2017 for breach of contract and misrepresentation concerning the G204 Study. Commenting on outcome, Manuel Llobet, CEO of Allergy Therapeutics, said: "ATL has always had full confidence in the Grass MATA MPL product and maintained that the inconclusive results of the G204 study were due to the inadequate procedures in the study. I am pleased that Inflamax have now compensated ATL for a significant proportion of the wasted study costs, as well as agreeing to pay the majority of the legal costs. Allergy Therapeutics aims to maintain the highest standards throughout its business and we are pleased that the matter has now been resolved."
jimmyloser
25/6/2019
11:25
About time Skygem topped up.
ewanwhose
14/6/2019
08:19
On Thursday Liu Xiaoming, China's ambassador to the UK, said that excluding Huawei from Britain's 5G network would "send a very bad signal". However, weak sterling gives Chinese investors an opportunity to buy more UK assets, says Monique Wong of Coutts. Chinese investment in the UK has largely been focused on the commercial property sector - "the iconic Cheesegrater was sold to Chinese investors a couple of years ago for just over a billion pounds", she says. "And don't forgot sterling is cheap, " she said, about 10% cheaper against the Chinese currency since the referendum. "It is an opportunity for Chinese investors and international investors more broadly," she said, adding that China's Fosun has expressed an interest in buying Thomas Cook's tour business. She also had a view on why was the market impact of the Hong Kong protests was limited - the Hang Seng stock index was down less than 0.5%. She said: "Usually the protests blow over... it doesn't really change our view on the region".
jimmyloser
11/6/2019
13:45
@jimmyloser Is Woodford buying in? If he was, the price would nosedive: maybe he's shorting it?
andrewbaker
11/6/2019
07:03
See above......Somebody likes the taste of peanuts. 15% of AGY for circa 11p a share !!!
jimmyloser
Chat Pages: 154  153  152  151  150  149  148  147  146  145  144  143  Older
Your Recent History
LSE
AGY
Allergy Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191023 12:36:38